RSS Feeds
Cost-Effectiveness of Cyclooxygenase-2 Inhibitors in Chronic Arthritis
- Brennan M.R. Spiegel, MD; and
- Ian M. Gralnek, MD, MSHS
- From Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA 90073.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
We thank Pellissier and colleagues for their interest in our study. Whereas we estimated that it costs more than $275 000 per quality-adjusted life-year gained to prescribe a coxib in lieu of naproxen in average-risk patients with arthritis, Pellissier and colleagues came to very different conclusions. Specifically, the authors estimated that it costs only $4738 more …
